Bentley to Present Results of Initial Phase II Intranasal Insulin Study

Bentley Pharmaceuticals has recently completed a data analysis of its Phase II clinical trial in Ireland of its proprietary intranasal insulin.

Bentley will report the results in an abstract, titled "Intranasal Insulin Administration in Type I Diabetic Patients Utilizing CPE-215 Technology" at the American Diabetes Association 65th Scientific Sessions, June 10-14.

Bentley previously reported successful completion of the study at the end of 2004. Previous studies of the intranasal insulin development program were published in Diabetes Technology and Therapeutics.